Pantoni Leonardo, Mele Francesco, Pescini Francesca, Rafanelli Martina, Zivelonghi Cecilia, Tomasi Luca, Mugnai Giacomo, Tomaselli Caterina, Petrone Alfredo, Adami Alessandro, Molon Giulio, Crea Pasquale, La Spina Paolino, Carullo Giuseppe, Galati Franco, Lumera Sebastiano, Giordano Antonello, Matteucci Giulia, Scopelliti Giuseppe, Forleo Giovanni, Ungar Andrea
Neuroscience Research Center, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
Department of Neurorehabilitation Sciences, Casa di Cura Igea, Milan, Italy.
Eur J Neurol. 2025 Jun;32(6):e70251. doi: 10.1111/ene.70251.
Long-term continuous monitoring with insertable cardiac monitor (ICM) is recommended after cryptogenic stroke (CS) by current guidelines to detect subclinical atrial fibrillation (SCAF). However, long-term real-world data on ICM-SCAF detection and ensuing therapy are limited. The aim of this study was to assess long-term SCAF detection rate in a large cohort of CS patients with ICM.
Data of consecutive CS patients receiving ICM from September 2016 to February 2024 in 20 Italian centers were collected. Patients were followed with remote and outpatient follow-up according to clinical practice. SCAF was diagnosed if a device-detected SCAF daily burden ≥ 5 min was confirmed by a cardiologist.
Seven hundred and eighty-nine CS patients with ICM (mean age 69.3 ± 11.7 years, 40.3% females, 79.0% CHADS-VASc score ≥ 4) were monitored for a mean of 27.3 (IQR:14.2-42.5) months after index stroke. SCAF was diagnosed in 229 (29.0%) patients, with a cumulative detection rate of 37.0% (IQR: 32.9%-41.5%) 48 months after the stroke, and was asymptomatic in 198 (86.5%). Sixty-eight (29.7%) patients had one or more days with a 24-h SCAF burden. Median time from index stroke to SCAF diagnosis was 6.9 (IQR: 2.1-17.0) months. After SCAF diagnosis, anticoagulants were prescribed to 210 (95.9%) patients out of 219 not already assuming them at baseline. CHADS-VASc ≥ 5, anterior circulation stroke, and cortical lesions were independent predictors of SCAF diagnosis.
This multicenter real-world project confirmed that ICM allows the detection of SCAF in one third of CS patients 48 months after the stroke, leading to anticoagulation in most of them.
当前指南建议,隐源性卒中(CS)后使用植入式心脏监测器(ICM)进行长期连续监测,以检测亚临床房颤(SCAF)。然而,关于ICM检测SCAF及后续治疗的长期真实世界数据有限。本研究的目的是评估一大群接受ICM的CS患者的长期SCAF检测率。
收集了2016年9月至2024年2月期间在20个意大利中心接受ICM的连续CS患者的数据。根据临床实践,对患者进行远程和门诊随访。如果心脏病专家确认设备检测到的SCAF每日负荷≥5分钟,则诊断为SCAF。
789例接受ICM的CS患者(平均年龄69.3±11.7岁,40.3%为女性,79.0%的CHADS-VASc评分≥4)在首次卒中后平均监测27.3(四分位间距:14.2-42.5)个月。229例(29.0%)患者被诊断为SCAF,卒中后48个月的累积检测率为37.0%(四分位间距:32.9%-41.5%),其中198例(86.5%)无症状。68例(29.7%)患者有一天或多天的24小时SCAF负荷。从首次卒中到SCAF诊断的中位时间为6.9(四分位间距:2.1-17.0)个月。在SCAF诊断后,219例基线时未服用抗凝剂的患者中有210例(95.9%)被开具了抗凝剂。CHADS-VASc≥5、前循环卒中及皮质病变是SCAF诊断的独立预测因素。
这个多中心真实世界项目证实,ICM能够在卒中后48个月检测出三分之一的CS患者的SCAF,并使大多数患者接受抗凝治疗。